# PCCA XemaTop™

Patent Pending Technology

For Use in Formulations for Patients with Eczema, Psoriasis and Xerosis

PCCA # 30-4891



## Targeted nourishment.

**XemaTop** is a base designed for use in compounding formulations for patients with eczema, psoriasis and xerosis (dry skin).

It uses the power and synergy of natural boswellic acid, avenanthramides from oats, phosphatidylglycerol and elegant film formers to deliver and improve the action of common active pharmaceutical ingredients (APIs) used in formulations for these patients.<sup>1</sup>

### **BENEFITS**

- Quickly replenishes the lamellar bilayers of the skin
- · Nourishes the skin's structural integrity
- Reduces the appearance of red and irritated skin
- Helps restore the skin's barrier to prevent water loss

## **RELATED SPECIALTIES**

- Dermatology
- · Family Practice

Anti-aging

Pediatrics

## **COMMONLY COMPOUNDED WITH**

- Corticosteroids
- Cyanocobalamin
- Vitamin D and derivatives
- · Zinc pyrithione
- Vitamin E and derivatives

### **FORMULATED WITHOUT**


Nuts

Soy

Gluten

• Egg

Dairy



### **ALSO AVAILABLE**

## **Clarifying** <sup>™</sup> Base

- Supports healthy skin and decreases oil formation
- Natural ingredients that may improve the appearance of red blotchy skin
- Works in conjunction with added APIs (such as benzoyl peroxide and antimicrobials)
- Uses the same emulsion platform the was used in the popular Rx Skin Therapy Clarifying Cream and Clarifying Facial Masque

PCCA #30-4845

Continued on the next page

## PCCA XemaTop™

**Patent Pending Technology** 



## FORMULAS WITH FORUMLAPLUS™ BEYOND-USE DATE (BUD) STUDIES

- PCCA Formula #12374
   Pentoxifylline 5% to 15% Topical Cream (XemaTop)
   (BUD Bracketed Study)
- PCCA Formula #12371
   Cyanocobalamin 0.07% to 1% Topical Cream (XemaTop)
   (BUD Bracketed Study)
- PCCA Formula #11788
   Zinc Pyrithione 0.2%/Clobetasol Propionate 0.05%
   Cyanocobalamin 0.07% Topical Cream (XemaTop)
   (BUD Study)
- PCCA Formula #11934
   Naltrexone HCl 1% Topical Cream (XemaTop)
   (BUD Study)
- PCCA Formula #12495
   Ketotifen 0.05% Topical Cream (XemaTop) (BUD Study)

To see our full list of XemaTop formulas, visit the <u>PCCA</u> <u>Members-Only Website</u>.

## FREQUENTLY ASKED QUESTIONS

## Is XemaTop a good base for anti-aging creams?

Yes, see PCCA Formula #11890 – Hyaluronic Acid/ Dexpanthenol/Plukenetia Volubilis Topical Cream (XemaTop) and PCCA Formula #12062 – Ascorbyl Palmitate 10%/Estriol 0.05%/Retinol Molecular 1% Topical Cream (XemaTop) on the Member-Only Website as examples.

**Can Xematop be relabeled and sold alone as a cosmetic?** Yes. Reference PCCA Document #99163 – "Cosmetic Labeling Guide – Base, PCCA XemaTop" on the Members-Only Website.

#### **STUDIES**

- 1. Technical Report: Evaluation of Different Formulations Applied to Psoriasis Tissue (Part 1/3)
- 2. Technical Report: Evaluation of Different Formulations Applied to Psoriasis Tissue (Part 2/3)
- 3. Technical Report: Evaluation of Different Formulations Applied to Psoriasis Tissue (Part 3/3)

To see all of our XemaTop studies in depth, visit pccarx.com/science.

## **PLEASE NOTE**

Always make sure you have checked the PCCA formula database and are following the most up-to-date version of a formula, as changes are continually made to existing formulations to provide the highest quality. The formulas and/or statements listed are provided for educational purposes only. They are compounding ideas that have commonly been requested by physicians and have not been evaluated by the Food and Drug Administration. Formulas and/or material listed are not to be interpreted as a promise, guarantee, or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

